IPO - Profile


We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Our portfolio currently includes GH001, our proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, our proprietary injectable 5-MeO-DMT product candidate.

We have completed a Phase 1 healthy volunteer clinical trial, in which administration of GH001 via inhalation was observed to More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$16.00 10,000,000 Positive High 16.5%

Offering Team

  • Legal counsel
  • David Lubin & Associates, PLLC
  • Auditors
  • PricewaterhouseCoopers S.A

Deal Highlights

Deal Tracker

IPO Dates

Filing 24 Jun, 2021

Offer 25 Jun, 2021

Look Ahead

Lock Up Expiry Dec 25, 2021

IPO Terms

Offer Price $16.00
Offer Size 10M

Market Sentiments

Stock Price